A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

The WOLVERINE study analyzed five trials and found metastasis-directed therapy-- primarily radiation -- may delay castration resistance and improve other long-term outcomes in prostate cancer. While ...

Prospective analysis of AR-V7 expression in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) sequentially treated with docetaxel and enzalutamide. This is an ASCO Meeting ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow up of ...

Investigators evaluated the benefit of leuprorelin immediately after radical prostatectomy for prostate cancer in patients with undetectable PSA levels.